Kramer et al. evaluated the safety and dosimetry of [177Lu]Lu-PSMA-ALB-56 in 10 mCRPC patients, showing improved blood circulation, higher absorbed doses in tumor lesions (2.3-fold), but significantly higher in kidney accumulation (8.2-fold) compared to PSMA-617 and PSMA I&T, hampering further clinical development (Figure 4A) 70. This evidence concerns the gene FOLH1 and neoplasm.